Lung Cancer Trial, Recruiting (NCT07243132)

Lung Cancer Trial, Recruiting NCT07243132 Sponsor: GFPC Investigation Condition: Lung Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07243132 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lung Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older
People who have been living with a stage III or stage IV type of lung cancer (called NSCLC or SCLC) for more than three years since their diagnosis, and who are not currently receiving a type of cancer treatment called cytotoxic chemotherapy (treatment with immunotherapy, targeted therapy, or monitoring alone is acceptable)
People covered by the French national health insurance system or an equivalent third-party health insurance scheme

Who may not be able to join:

People who have difficulty understanding French
People currently receiving cytotoxic chemotherapy (a specific type of cancer-killing treatment)
People who are under a legal protection measure such as guardianship, curatorship, or tutorship
People whose cognitive capacity (ability to think and understand) is not sufficient to answer questionnaires
People for whom collecting data would not be possible, for example due to being lost to follow-up or refusing data collection
People who do not wish their personal data to be collected for the study (an information sheet will be provided explaining this)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lionel FALCHERO, GFPC

Phone: +33 (0)4 73 98 39 86

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07243132

Sponsor: GFPC Investigation

Phase: Not Applicable

Status: Recruiting

Condition: Lung Cancer

Trial contact: +33 (0)4 73 98 39 86

More information: https://clinicaltrials.gov/study/NCT07243132

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older
People who have been living with a stage III or stage IV type of lung cancer (called NSCLC or SCLC) for more than three years since their diagnosis, and who are not currently receiving a type of cancer treatment called cytotoxic chemotherapy (treatment with immunotherapy, targeted therapy, or monitoring alone is acceptable)
People covered by the French national health insurance system or an equivalent third-party health insurance scheme

Who may not be able to join:

People who have difficulty understanding French
People currently receiving cytotoxic chemotherapy (a specific type of cancer-killing treatment)
People who are under a legal protection measure such as guardianship, curatorship, or tutorship
People whose cognitive capacity (ability to think and understand) is not sufficient to answer questionnaires
People for whom collecting data would not be possible, for example due to being lost to follow-up or refusing data collection
People who do not wish their personal data to be collected for the study (an information sheet will be provided explaining this)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

GFPC Investigation

Registry

ClinicalTrials.gov

Start date

2 July 2025

Est. completion

31 January 2031

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Baseline Clinical Characteristics; Aix-Marseille-University (AMU) questionnaire; EORTC QLQ-LC13; Hospital Anxiety and Depression Scale (HAD); Treatment characteristics; Health status; Socio-demographic characteristics

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov